Epigallocatechin-3-gallate Can Prevent Type 2 Human Papillomavirus E7 from Suppressing Interferon-Stimulated Genes

Ji Young Song1,2, Ju Hee Han2, Yumee Song2

  • 1Program of Immunology & Microbiology, Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea.

Insights

Low-risk human papillomavirus (HPV) type 2 E7 protein suppresses antiviral interferon-stimulated genes (ISGs). Epigallocatechin-3-gallate (EGCG) may prevent cutaneous warts by upregulating these ISGs.

Area of Science:

  • Virology
  • Immunology
  • Dermatology

Background:

  • High-risk human papillomavirus (HPV) suppresses type I interferon (IFN) signaling and interferon-stimulated genes (ISGs).
  • The impact of low-risk HPV on ISG expression and antiviral functions remains unclear.

Purpose of the Study:

  • To investigate the expression of antiviral ISGs in keratinocytes transfected with the type 2 HPV (HPV-2) E7 protein.
  • To evaluate the potential of epigallocatechin-3-gallate (EGCG) in modulating HPV-induced ISG suppression.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qPCR) to assess mRNA expression.
  • Western blot and immunofluorescence/immunohistochemistry to evaluate protein expression.
  • Transfection with HPV-2 E7, E7 siRNA, and EGCG pretreatment in keratinocytes.

Main Results:

  • HPV-2 positive cutaneous warts showed significantly decreased ISG mRNA expression compared to normal skin.
  • HPV-2 E7 transfection significantly downregulated ISG and type I IFN signaling pathway components.
  • EGCG pretreatment upregulated ISG and type I IFN signaling pathway components suppressed by HPV-2 E7.

Conclusions:

  • The E7 protein of low-risk HPV-2 downregulates antiviral ISGs and type I IFN signaling.
  • EGCG demonstrates potential as a preventive agent for cutaneous warts by restoring ISG expression.

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
619
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.3K